Acta Neuropathologica

, 118:599

Monoclonal antibody specific for IDH1 R132H mutation

  • David Capper
  • Hanswalter Zentgraf
  • Jörg Balss
  • Christian Hartmann
  • Andreas von Deimling
Short Report

Abstract

IDH1 R132H mutations occur in approximately 70% of astrocytomas and oligodendroglial tumors. We developed a mouse monoclonal antibody targeting the IDH1 R132H mutation. Here, we show the high specificity and sensitivity of this antibody on Western blots and tissue sections from formalin fixed paraffin embedded tumor specimens. This antibody is highly useful for tumor classification, in detecting single infiltrating tumor cells and for the characterization of the cellular role of mutant IDH1 protein.

Keywords

IDH1 Monoclonal antibody Immunohistochemistry Astrocytoma Oligodendroglioma Oligoastrocytoma 

References

  1. 1.
    Balss J, Meyer J, Mueller W et al (2008) Analysis of the IDH1 codon 132 mutation in brain tumors. Acta Neuropathol 116:597–602CrossRefPubMedGoogle Scholar
  2. 2.
    Bleeker FE, Lamba S, Leenstra S et al (2009) IDH1 mutations at residue p.R132 (IDH1(R132)) occur frequently in high-grade gliomas but not in other solid tumors. Hum Mutat 30:7–11CrossRefPubMedGoogle Scholar
  3. 3.
    Harlow E, Lane D (1988) Antibodies: a laboratory manual. Cold Spring Harbor Laboratory, Cold Spring HarbourGoogle Scholar
  4. 4.
    Hartmann C, Meyer J, Balss J et al (2009) Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1010 diffuse gliomas. Acta Neuropathol 118:469–474CrossRefPubMedGoogle Scholar
  5. 5.
    Ichimura K, Pearson DM, Kocialkowski S et al (2009) IDH1 mutations are present in the majority of common adult gliomas but are rare in primary glioblastomas. Neuro Oncol 11:341–347CrossRefPubMedGoogle Scholar
  6. 6.
    Kang MR, Kim MS, Oh JE et al (2009) Mutational analysis of IDH1 codon 132 in glioblastomas and other common cancers. Int J Cancer 125:353–355CrossRefPubMedGoogle Scholar
  7. 7.
    Köhler G, Milstein C (1975) Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256:495–497CrossRefPubMedGoogle Scholar
  8. 8.
    Mardis ER, Ding L, Dooling DJ et al (2009) Recurring mutations found by sequencing an acute myeloid leukemia genome. N Engl J Med 361:1058–1066CrossRefPubMedGoogle Scholar
  9. 9.
    Parsons DW, Jones S, Zhang X et al (2008) An integrated genomic analysis of human glioblastoma multiforme. Science 321:1807–1812CrossRefPubMedGoogle Scholar
  10. 10.
    Sanson M, Marie Y, Paris S et al (2009) Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas. J Clin Oncol 27:4150–4154CrossRefPubMedGoogle Scholar
  11. 11.
    Watanabe T, Nobusawa S, Kleihues P et al (2009) IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas. Am J Pathol 174:653–656Google Scholar
  12. 12.
    Weller M, Felsberg J, Hartmann C et al (2009) Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma. A prospective translational study of the German Glioma Network. J Clin Oncol (in press)Google Scholar
  13. 13.
    Wick W, Stoffels M, Engel C et al (2009) NOA-04 Randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with PCV or temozolomide. J Clin Oncol (in press)Google Scholar
  14. 14.
    Yan H, Parsons DW, Jin G et al (2009) IDH1 and IDH2 mutations in gliomas. N Engl J Med 360:765–773CrossRefPubMedGoogle Scholar
  15. 15.
    Zhao S, Lin Y, Xu W et al (2009) Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1alpha. Science 324:261–265CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag 2009

Authors and Affiliations

  • David Capper
    • 1
  • Hanswalter Zentgraf
    • 2
  • Jörg Balss
    • 3
  • Christian Hartmann
    • 1
    • 3
  • Andreas von Deimling
    • 1
    • 3
  1. 1.Department of Neuropathology, Institute of PathologyRuprecht-Karls-University HeidelbergHeidelbergGermany
  2. 2.Monoclonal Antibody UnitGerman Cancer Research CenterHeidelbergGermany
  3. 3.Clinical Cooperation Unit Neuropathology G380German Cancer Research CenterHeidelbergGermany

Personalised recommendations